Clinical trial NCT05665088: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Agitation
Dementia
Lead sponsor: BioXcel Therapeutics Inc
Sponsor class: INDUSTRY
Collaborators: name: Cognitive Research Corporation
First posted: 2022-12-27
Enrollment: 13
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized
Primary purpose: TREATMENT

Brief summary: A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 168 doses within a 12-week treatment period.

Detailed description: A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female subjects (65 years and older) with acute psychomotor agitation associated with dementia.

Approximately 150 subjects will participate in this study. Subjects will receive a single film consisting of BXCL501 40 µg dose or BXCL501 60 µg dose or placebo. Subjects must reside in a care facility where all study-related procedures and study drug dosing will be performed.

Eligibility criteria: Inclusion Criteria:

1. All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AA criteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria
2. Episodes of psychomotor agitation (e.g., kick, bite, flailing)
3. Subjects exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior
4. A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to full assistance with activities of daily living
5. Subjects who read, understand, and provide written informed consent, or who have a LAR to provide consent on their behalf
6. Subjects who are deemed to be medically appropriate for study participation by the principal investigator
7. Participants who agree to use a medically acceptable and effective birth control method

Exclusion Criteria:

1. Subjects with dementia or other memory impairment not due to probable AD.
2. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function.
3. Subjects with agitation caused by acute intoxication.
4. Subjects with significant risk of suicide or homicide per the investigator's assessment.
5. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (\>5 years) history of stroke may be included, regardless of size/location.
6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia.
7. Subjects with laboratory or ECG abnormalities.
8. Subjects who have received an investigational drug within 30 days prior to Screening.
9. Subjects who are currently suffering from substance abuse.
10. Subjects with a potential cause for delirium (relatively recent onset agitation and dementia)

Primary outcomes:
measure: Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
timeFrame: 120 minutes post-dose for first episode of agitation
Secondary outcomes:
measure: Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
timeFrame: 60 minutes post-dose for first episode of agitation
measure: Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
timeFrame: 30 minutes post-dose for first episode of agitation
Other outcomes:
Locations:
city: Los Alamitos
country: United States
facility: BioXcel Clinical Research Site
state: California
city: Daytona Beach
country: United States
facility: BioXcel Clinical Research Site
state: Florida
city: Maitland
country: United States
facility: BioXcel Clinical Research Site
state: Florida
city: The Villages
country: United States
facility: BioXcel Clinical Research Site
state: Florida
city: Marrero
country: United States
facility: BioXcel Clinical Research Site
state: Louisiana
city: Springfield
country: United States
facility: BioXcel Clinical Research Site
state: Massachusetts
city: Toms River
country: United States
facility: BioXcel Clinical Research Site
state: New Jersey
Study officials:
affiliation: BioXcel Therapeutics
name: Robert Risinger, MD
role: STUDY_CHAIR
References: